Clinical trial NCT01821612: Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
Official title: Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: an Intergroup Single-Arm Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Acinar Cell Adenocarcinoma of the Pancreas
Duct Cell Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Lead sponsor: Alliance for Clinical Trials in Oncology
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2013-04-01
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This pilot clinical trial studies combination chemotherapy and radiation therapy before surgery followed by gemcitabine hydrochloride in treating patients with pancreatic cancer. Drugs used in chemotherapy, such as oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery.

Detailed description: The purpose of this study is to evaluate a new treatment program for patients with borderline resectable pancreas cancer in order to determine what effects, good and bad, chemotherapy and chemoradiation have on your cancer and to see if it allows safe surgery.

Primary Objectives:

* To assess the accrual rate of this study.
* To assess the rate of treatment-related toxicity and treatment delay during preoperative therapy.
* To assess the rate of completion of all preoperative and operative therapy.

Secondary Objectives:

* To assess the macroscopic (R0/R1) resection rate.
* To estimate the rate of radiographic and histopathologic response to preoperative therapy.
* To estimate the time to locoregional and distant recurrence.
* To assess overall survival (OS).
* To retrieve nucleic acids from pretreatment pancreatic ductal adenocarcinoma biopsies and to assess the quality of these nucleic acids using a sequencing-based assessment of tumor DNA.

Eligibility criteria: Pre-Registration Eligibility Criteria

* Documentation of Disease and Radiographic Staging

  * Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinate process
  * Objective radiographic staging with a) contrast-enhanced, helical thin-cut computed tomography (CT)/magnetic resonance imaging (MRI) scan of the abdomen and b) CT scan/MRI of the chest
  * Note: echoendoscopic staging will be permitted as an adjunctive modality, but all stage definitions below will be determined using CT/MRI as outlined below. In the event echoendoscopic stage and CT/MRI stage are discordant, the CT/MRI stage will be used. Significant discordance should be discussed with the study principal investigator (PI) prior to enrollment
  * Borderline resectable primary tumor, defined by the presence of any one or more of the following on CT/MRI, and confirmed by central radiographic review:

    * An interface between the primary tumor and the superior mesenteric vein or portal vein (SMV-PV) measuring ≥ 180 degrees of the circumference of the vessel wall
    * Short-segment occlusion of the SMV-PV with normal vein above and below the level of obstruction that is amenable to resection and venous reconstruction
    * Short segment interface (of any degree) between tumor and hepatic artery with normal artery proximal and distal to the interface that is amenable to resection and reconstruction
    * An interface between the tumor and superior mesenteric artery (SMA) measuring \< 180 degrees of the circumference of the vessel wall
  * No potentially resectable disease defined as primary tumors with all of the following:

    * An interface between the primary tumor and the superior mesenteric vein or portal vein (SMV-PV) measuring \< 180 degrees of the circumference of the vessel wall
    * No radiographic interface between the tumor and the (superior mesenteric artery) SMA, hepatic artery or celiac axis
    * No radiographic evidence of metastatic disease
  * No metastatic disease defined as any one or more of the following:

    * Suspicious lymphadenopathy outside the standard surgical field (i.e., aortocaval nodes, distant abdominal nodes)
    * Radiographic evidence for metastatic disease in distant organs, such as masses in distant organs or ascites
  * No locally advanced and/or unresectable disease clearly defined by any one or more of the following by CT/MRI:

    * An interface between the tumor and the SMA measuring ≥ 180 degrees of the circumference of the vessel wall
    * No interface between the tumor and the aorta
    * Occlusion of the SMV or portal vein without a sufficient cuff of normal vein above and below the level of obstruction with which to perform venous reconstruction
    * Long-segment interface (of any degree) between the tumor and the common hepatic artery or its major tributaries with insufficient artery proximal and distal to the interface to perform reconstruction
* No prior chemotherapy or chemoradiation for pancreatic cancer
* No patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years
* Baseline peripheral sensory neuropathy must be grade \< 2
* No patients with known Gilbert's Syndrome or homozygosity for UGT1A1\*28 polymorphism
* No history of pulmonary embolism in the past 6 months
* Age ≥ 18 years of age
* Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status 0-1
* Pregnancy/Nursing Status: Non-pregnant and non-breast-feeding. Female participants of child-bearing potential must have a negative urine or serum pregnancy test prior to registration. Perimenopausal participants must be amenorrheic \> 12 months to be considered not of childbearing potential.
* Required Pre-Registration Laboratory Values:

  * Granulocytes ≥ 2,000/ul
  * Hemoglobin \> 9 g/dL
  * Platelets ≥ 100,000/ul
  * Albumin \> 3.0 g/dL
  * Creatinine ≤1.5 x upper limit of normal (ULN)

Registration Eligibility Criteria

* Confirmation of pre-registration eligibility criteria as described under "Documentation of Disease and Radiographic Staging" by the Alliance Central Radiographic Review
* Required Registration Laboratory Values:

  * Bilirubin ≤2 mg/dl
  * AST (SGOT) \& ALT (SGPT) ≤ 2.5 x ULN

Primary outcomes:
measure: Accrual rate, calculated by total number of patients accrued divided by number of months from the date the study is opened at the fifth site to the evaluation date
timeFrame: Up to 3 years
measure: Rate of treatment-related toxicity during preoperative therapy assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4
timeFrame: Up to 30 days after completion of study treatment
measure: Rate of treatment delay (greater than 4 weeks) during preoperative therapy
timeFrame: Up to 28 weeks
measure: Completion rate of all preoperative and operative therapy
timeFrame: Up to 30 weeks
Secondary outcomes:
measure: Macroscopic (R0/R1) resection rate defined as number of patients achieved R0 or R1 resection during surgery divided by number of evaluable patients
timeFrame: At the time of surgery
measure: Radiographic response rate defined as number of patients who achieved complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during pre-operative therapy divided by the number of evaluable patients
timeFrame: Up to 18 weeks
measure: Histopathologic response rate defined as number of patients who achieved CR or PR determined according to histopathologic examination during pre-operative therapy divided by the number of evaluable patients
timeFrame: Up to 18 weeks
measure: Time to locoregional recurrence
timeFrame: From the date of registration to the date of the first documented locoregional recurrence, assessed up to 3 years
measure: Time to distant recurrence
timeFrame: From the date of registration to the date of the first documented distant recurrence, assessed up to 3 years
measure: Overall survival
timeFrame: From the date of registration to the date of the death due to all causes, assessed up to 3 years
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UC San Diego Moores Cancer Center
state: California
city: Chicago
country: United States
facility: University of Chicago Comprehensive Cancer Center
state: Illinois
city: Evanston
country: United States
facility: NorthShore University HealthSystem-Evanston Hospital
state: Illinois
city: Louisville
country: United States
facility: The James Graham Brown Cancer Center at University of Louisville
state: Kentucky
city: New Orleans
country: United States
facility: Ochsner Medical Center Jefferson
state: Louisiana
city: Baltimore
country: United States
facility: Johns Hopkins University/Sidney Kimmel Cancer Center
state: Maryland
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
city: Cincinnati
country: United States
facility: University of Cincinnati
state: Ohio
city: Columbus
country: United States
facility: Ohio State University Comprehensive Cancer Center
state: Ohio
city: West Chester
country: United States
facility: University Pointe
state: Ohio
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
city: Madison
country: United States
facility: University of Wisconsin Hospital and Clinics
state: Wisconsin
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Matthew Katz, M.D.
role: STUDY_CHAIR
References:
citation: Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 Aug 17;151(8):e161137. doi: 10.1001/jamasurg.2016.1137. Epub 2016 Aug 17.